Skip to main content
. 2020 Sep 3;4(17):4113–4123. doi: 10.1182/bloodadvances.2020002184

Figure 3.

Figure 3.

Assessment of immunologic correlative studies. (A) Time course of major cell populations at baseline and through 2 years of alloHCT, including lymphocyte counts (PBL), total T cells (CD3+), CD4+ and CD8+ T cells, B cells (CD19+CD5−), NK cells (CD56+CD3−), and dendritic cells (HLA-DR+LINEAGE−). Each dot represents median value of absolute counts. (B) CD4Treg/CD4Tcon ratio over time. (C) CD4Treg and CD4Tcon median percentage of effector memory (EM), central memory (CM), naive and terminally differentiated (TD) cells. (D) Absolute counts of B cells (CD19+CD5−), antigen-naive B cells (CD19+CD5−27−), and antigen experienced B cells (CD19+CD5−27+). Each dot represents median value. *P < .05 and **P < .01 compared with the prior chemoimmunotherapy.